Sandoz Group AG/€SDZ

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Sandoz Group AG

Sandoz Group AG operates in the pharmaceutical industry, specializing in the development, manufacturing, and distribution of generic medicines and biosimilars. The company's product portfolio includes a wide range of therapeutic areas, such as antibiotics, oncology, and cardiovascular treatments. Sandoz was founded as part of a broader restructuring that involved the separation from Novartis in 2022, with a focus on enhancing the accessibility of high-quality healthcare solutions. Headquartered in Switzerland, Sandoz has a significant global presence with operations spanning across numerous countries. The company emphasizes cost-effective healthcare, leveraging a substantial manufacturing and research capacity to maintain competitive strengths in the global pharmaceutical market.

Ticker

€SDZ
Sector
Health

Primary listing

XGAT

Employees

20,000

Headquarters

Basel, Switzerland
Website
www.sandoz.com

Sandoz Group AG Metrics

BasicAdvanced
€22B
115.94
€0.45
-
€0.64
1.24%

Bulls say / Bears say

Sandoz’s alliance with Johnson & Johnson to co-market the ustekinumab biosimilar Pyzchiva in the U.S. leverages J&J’s sales strength and deepens Sandoz’s position in high-value immunology, supporting near-term revenue growth (Reuters).
By suing Amgen for antitrust and seeking to overcome patent obstacles blocking its Erelzi biosimilar, Sandoz is targeting entry into the $3.3 billion U.S. Enbrel market, with the potential to materially grow its biosimilar revenues if successful (Reuters).
With plans to introduce semaglutide-based weight-loss generics in Canada at up to 70% lower prices after patents expire in January 2026, Sandoz is diversifying into the fast-growing GLP-1 segment, positioning itself for strong sales growth in a rapidly expanding market (FT).
Sandoz’s $275 million settlement to resolve U.S. consumer drug price-fixing claims, on the heels of a $265 million deal last year, underscores ongoing legal risks and reputational issues that could impact future earnings (Reuters).
CEO Richard Saynor cautioned that proposed U.S. tariffs on generic drugs may force Sandoz to withdraw certain products from the U.S. market, threatening its largest regional revenue stream (Reuters).
Sandoz’s plan to cut prices of semaglutide-based weight-loss generics in Canada by as much as 70%, while likely to grow volumes, could squeeze margins and put pressure on supply chains, thereby hurting overall profitability (FT).
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy €SDZ

Sign up or log in to buy
Capital at risk
Extended hours trading

Upcoming events

No upcoming events
FAQs